Takeda is offering about $5 billion to purchase Abbott’s stake of their U.S. joint venture. TAP has marketed two blockbusters – Prevacid and Lupron – but has recently stumbled.
Meanwhile, Takeda has been trying to grow its own organic presence in the U.S. Takeda will be getting TAP’s reps and its building north of Chicago.
Meanwhile, Takeda has been trying to grow its own organic presence in the U.S. Takeda will be getting TAP’s reps and its building north of Chicago.